Gair, Gair, Conason, Rubinowitz, Bloom, Hershenhorn, Steigman & Mackauf is a New York Plaintiff's personal injury law firm specializing in automobile accidents, construction accidents, medical malpractice, products liability, police misconduct and all types of New York personal injury litigation.

Articles Posted in Medical Malpractice

Published on:

Our Partner Robert L. Conason is on The Faculty of This program which will be held from October 12 – 14, 2009 at the Marriott Eastside Hotel, New York, New York.

This CME program is designed to cover clinical aspects of breast imaging including conventional and digital mammography, breast ultrasound, breast MRI, and interventional procedures, as well as medicolegal issues. The faculty consists of nine nationally and internationally recognized experts. The program of lectures and panel discussions will be filled with “take home” information that should benefit every breast imaging practice. Bob will be speaking on October 14, 2009 0n Breast Imaging Malpractice: An Attorney’s Perspective. For more information click here.

Published on:

Our Partner, Stephen H. Mackauf is The Co-Chair of The American Conference Institutes’s 8th Annual Advanced Forum on Preventing, Managing and Defending Claims of Obstetric Malpractice. The Forum will be held on June 23 & 24, 2009 at The Union League of Philadelphia-Philadelphia, PA. Stephen will also be participating in a Post-Conference Workshop on June 24th, “The Attorney’s Guide to Handling an Infant Brain Injury Case from Start to Finish.” Stephen will also be speaking on Fetal Monitoring and Surveillance: Making the Right Decisions Based on the Right Information. For more information click here.

Published on:

Our Partner Stephen H. Mackauf will be participating in a two day Seminar, “Defending the Delivery Team: Obstetric Malpractice” sponsored by Legal iQ. The program will be held in San Francisco on April 28th and 29th, 2009. Stephen will be discussing the Plaintiff’s perspective. For more information click here.

Published on:

Our partner Robert Conason will be speaking at the International Institute for Continuing Medical Education, Inc.’s Mount Sinai Update 2008: Breast Imaging. Bob will be speaking as to the plaintiff’s viewpoint on Breast Imaging Malpractice: An Attorney’s Perspective. The program is scheduled for October 13 – 15, 2008. The program will be held at The Marriott Hotel in New York City. Bob will be speaking at 10:30 A.M. on October 15th on Breast Imaging Malpractice and at 11:30 A.M. on Medicolegal Issues. For more information on this program click here.
Published on:


Our partners Jeffrey Bloom and Richard Steigman have co-authored an article entitled “The Impact of Arons: A Look at the Court of Appeals’ Decision to Allow Ex Parte Interviews of Treating Doctors and Where We Go from Here.” The Article is in The Spring 2008 Edition of Bill Of Particulars published by The New York State Trial Lawyers Institute.

Published on:

Murray v. New York City Health & Hospitals Corporation June 24th, 2008 WARNING

The 2d. Department upheld the dismissal of plaintiff’s action for wrongful death resulting from medical malpractice when the plaintiff’s counsel failed to appear for a final conference. The Court held;

“To be relieved of the default in appearing, the plaintiff was required to demonstrate both a reasonable excuse for the default and a meritorious cause of action (see CPLR 5015[a][1]; Brownfield v Ferris, 49 AD3d 790; Zeltser v Sacerdote, 24 AD3d 541, 542; Solomon v Ramlall, 18 AD3d 461). The vague and unsubstantiated allegations of the plaintiff’s counsel regarding law office failure did not amount to a reasonable excuse (see St. Luke’s Roosevelt Hosp. v Blue Ridge Ins. Co., 21 AD3d 946, 947; Solomon v Ramlall, 18 AD3d 461; Fennell v Mason, 204 AD2d 599). The further allegations regarding law office failure contained in counsel’s affirmation that was submitted for the first time in the reply papers of the plaintiff’s motion, in effect, for leave to reargue were properly rejected by the court (see Parkin v Ederer, 27 AD3d 633; Juseinoski v Board of Educ. of City of N.Y., 15 AD3d 353, 355). Furthermore, the plaintiff failed to submit an affidavit of merit from a medical expert (see Mosberg v Elahi, 80 NY2d 941; Salch v Paratore, 60 NY2d 851, 852; Hassell v New York Univ. Med. Ctr., 48 AD3d 632; Yushavayev v Kopelman, 307 AD2d 996; Burke v Klein, 269 AD2d 348). Accordingly, the Supreme Court properly granted the defendant’s motion for leave to enter judgment against the plaintiff and properly denied those branches of the plaintiff’s cross motion which were to vacate the dismissal of theaction and to restore the action to active status.”
Published on:

LOSS OF VISION FOLLOWING BLEPHAROPLASTY AS A RESULT OF ORBITAL HEMORRHAGE

Blepharoplasty basically is surgery in which excess tissue is removed from the eyelids. It is the most commonly performed cosmetic surgery of the face. Upper eyelid surgery is usually performed for removal of excess skin, muscle and fat and lower lid surgery for the removal of fat pads, so called baggy eyelids caused by herniation of periorbital fat.

The most serious complication of blepharoplasty is partial or complete loss of vision, most commonly as a result of intra-orbital hemorrhage. A widely accepted theory suggests orbital bleeding increases intraorbital and intraocular pressure, compromises the ocular circulation, and results in ischemic or optic nerve damage. Ischemic optic neuropathy and central artery occulsion are believed to be the most common final events in most cases of blindness after blepharoplasty. (Lowry JC, Bartley GB: Complications of Blepharoplasty. Surv. Ophthalmol 38:327-350, 1994).

Published on:

FAILURE TO PROPERLY TREAT EXTRAVASATION OF DOXORUBICIN (Adriamycin)

By: Anthony H. Gair;

New York medical malpractice attorney elaborates on the extravasation of intravenously administered chemotherapeutic agents into the subcutaneous tissue of cancer patients undergoing chemotherapy is a known risk of treatment. The potential gravity of injury caused by extravasation is dependent upon the type of drug which extravasates. The most destructive extravasation injuries are those caused by anti-tumor drugs which bind to deoxyribonucleic acid (DNA), such as Doxorubicin, (Adriamycin) which has been a primary part of chemotherapeutic regimes since the late 1960’s. Extravasation of chemotherapeutic agents which bind to nucleic acids can lead to a prolonged course of injury. The most clinical experience has been derived from the extravasation of Doxorubicin. Rudolph, R, Larson, D. Etiology and Treatment of Chemotherapeutic Agent Extravasation Injuries: A Review. J. Clin. Oncol, 1987; 5:1116-1126. Doxorubicin causes severe progressive tissue necrosis that may involve muscles and tendons. Since no specific antidote has been developed, the recommended treatment of Doxorubicin extravasation is early excission of all infiltrated tissue. Dahlstrom, KK, Chenoufi, HL, Daujard, S. Fluorescene microscopic demonstration and demarcation of Doxorubicin extravasation. Experimental and Clinical studies. Cancer, 1990 Apr. 15; 65(8): 1722-1726.

Published on:

A Study To End the Frivolous Malpractice Lawsuit Myth

This article written by our partner Jeffrey B. Bloom in 2006 is just as relevant today as it was then.

“Last week, within days of the U.S. Senate performing its annual rite of taking up and then denying cloture to a bill to limit the rights of medical malpractice victims and cap damages in medical malpractice cases, a study was released which clearly demonstrates that our current tort system is working quite well in ensuring that the vast majority of cases are valid claims and that frivolous or non-meritorious malpractice cases are rarely brought and hardly ever result in damages being unjustly paid.